Stock GUARD GUARD THERAPEUTICS INTERNATIONAL AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Market Closed - Nasdaq Stockholm
Other stock markets
 07:52:04 02/05/2024 pm IST 		5-day change 1st Jan Change
30 SEK +2.74% Intraday chart for Guard Therapeutics International AB +1.35% -16.20%
15/04 Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER CI
21/02 Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER
AQ
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER
CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Guard Therapeutics presented development strategy and new preclinical results at R&D Update
AQ
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update
CI
Invitation to Guard Therapeutics’ R&D Update on January 30
AQ
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges
MT
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035
AQ
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035
CI
Guard Therapeutics presents the Nomination Committee for 2024
AQ
Guard Therapeutics International AB Appoints Nomination Committee for 2024
CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023
AQ
Guard Therapeutics provides more information on the development strategy for RMC-035
AQ
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035
CI
Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program
AQ
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program
CI
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Last patient visit completed in Guard Therapeutics' clinical Phase 2 study AKITA
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUARD Stock
  4. News Guard Therapeutics International AB